Table 5.

Phase 3 and above Inactivated virus vaccine candidates for COVID-19

Inactivated Virus Vaccine Candidates Phase 3 and above (Source: WHO as per 15th October 2021)
Candidate	Dose	Schedule	Route of Administration	Phase	Developer
BBIBP-CorV (Vero Cell)	2	Day 0 + 21	Intramuscular	Phase 4 NCT04863638	Sinopharm, China National Biotec Group Co, Beijing Institute of Biological Products
CoronaVac	2	Day 0 + 14	Intramuscular	Phase 4 NCT04756830 NCT04747821 NCT04775069 NCT04789356 NCT04754698 NCT04801888 NCT04894227 NCT04892459 NCT04911790 NCT04953325 NCT04962308 NCT04993365 NCT05057169	Sinovac Research and Development Co., Ltd
Vero cell	2	Day 0 + 21	Intramuscular	Phase 3 ChiCTR2000034780 ChiCTR2000039000 NCT04510207 NCT04612972	Sinopharm and China National Biotec Group Co and Wuhan Institute of Biological Products
SARS-CoV-2 vaccine (vero cells)	2	Day 0 + 28	Intramuscular	Phase 3 NCT04659239	Institute of Medical Biology and Chinese Academy of Medical Sciences
QazCovid-in®	2	Day 0 + 21	Intramuscular	Phase 3 NCT04691908	Research Institute for Biological Safety Problems, Rep of Kazakhstan
BBV152	2	Day 0 + 14	Intramuscular	Phase 3 NCT04641481 CTRI/2020/11/028976	Bharat Biotech International Limited
VLA2001	2	Day 0 + 21	Intramuscular	Phase-3 NCT04864561	Valneva, National Institute for Health research, United Kingdom
ERUCOV-VAC	2	Day 0 + 21	Intramuscular	Phase-3 NCT04942405	Erciyes University, Turkey
Inactivated vaccine (Vero cell)	2	Day 0 + 28	Intramuscular	Phase-3 NCT04852705	Shenzhen Kangtai Biological products Co., Ltd